Cambium Bio (ASX:CMB) OCF Margin %: 0.00% (As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio OCF Margin %?

Cambium Bio ASX:CMB -6.74% 35 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Cambium Bio ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Cambium Bio's Cash Flow from Operations for the six months ended in Dec. 2025 was A$-1.24 Mil. Cambium Bio's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Cambium Bio's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Cambium Bio's current OCF Yield % is -30.02%.

The historical rank and industry rank for Cambium Bio's OCF Margin % or its related term are showing as below:


During the past 12 years, the highest OCF Margin % of Cambium Bio was -15600.00%. The lowest was -15600.00%. And the median was -15600.00%.

ASX:CMB's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Cambium Bio OCF Margin % Related Terms

Cambium Bio OCF Margin % Historical Data

* Premium members only.

The historical data trend for Cambium Bio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio OCF Margin % Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -15,600.00 0.00

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Cambium Bio's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-5.25/0
= %

Cambium Bio's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.239/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Cambium Bio (ASX:CMB) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #999999 out of 959 companies in the Biotechnology industry.
Is Cambium Bio's OCF Margin % too high?
Cambium Bio's current OCF Margin % is 0.00%. Based on the distribution chart, Cambium Bio ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #999999 out of 959 companies for OCF Margin %. This places Cambium Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cambium Bio and its competitors. Cambium Bio's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price